Alterations of 19q13 are frequently observed in glial neoplasms, suggesting that this region harbors at least one gene involved in gliomagenesis. Following our previous studies on structural 19q chromosome rearrangements in gliomas, we have undertaken a detailed FISH analysis of the breakpoints and identified a 19q13.2 intrachromosomal amplification of the MAP/microtubule affinityregulating kinase 4 (MARK4) gene in three primary glioblastoma cell lines. Recent data suggest that this gene is involved in the Wnt-signaling pathway. We observed that the expression of the alternatively spliced MARK4L isoform is upregulated in both fresh and cultured gliomas and overexpressed in all of the above three glioblastoma cell lines. Interestingly, we also found that MARK4L expression is restricted to undifferentiated neural progenitor cells or proliferating glial precursor cells, whereas its expression is downregulated during glial differentiation. Perturbation of expression using antisense oligonucleotides against MARK4 in glioblastoma cell lines, consistently induced a decreased proliferation of tumor cells. Taken together, these data show that MARK4, which is normally expressed in neural progenitors, is reexpressed in gliomas and may become a key target of intrachromosomal amplification upon 19q rearrangements.
Introduction
Gliomas are the most common primary neuroepithelial tumors that develop in the central nervous system (CNS). Premalignant stages have not been recognized, but the multistep process underlying development and progression of glial neoplasms has been dissected through the analysis of large series of tumors of different malignancy grade . Whether gliomas arise from a glial-restricted progenitor or from a dedifferentiated oligodendrocyte or astrocyte, molecular analysis has shown that specific pathways that control the differentiation of glial precursor cells become disregulated (Nobel and Mayer-Proschel, 1997 ). Molecular genetic studies have demonstrated that both inactivation of tumor-suppressor genes as well as oncogene amplification are important in the malignant progression of human gliomas (Holland, 2001 ). In particular, critical genes coding for growth factors, and their receptors (Ekstrand et al., 1991; Takahashi et al., 1992; Wong et al., 1992; Guha et al., 1995) , as well as genes involved in cell cycle regulation (El-Azouzi et al., 1989; Jen et al., 1994; Henson et al., 1994; Reifenberger et al., 1994) are differentially overexpressed or altered in glial tumors. The progression to glioblastoma multiforme (GBM) involves losses of expression of tumor-suppressor proteins on chromosome 10 in a subset of tumors (Mollenhauer et al., 1997; Sano et al., 1999) . Despite these observations, however, there are still other critical genes that map to other amplified or deleted chromosomal regions, which have not yet been identified (Schrock et al., 1994) . Of all of the recurrent structural chromosome aberrations that have been described in gliomas, abnormalities involving 19q13 occur in virtually all stages and variants of gliomas, suggesting that genes on this chromosome have a fundamental importance in gliomagenesis and normal glial differentiation (von Deimling et al., 1992; Ritland et al., 1995) . Where deletions have been observed, the minimal deletion interval has been progressively narrowed down to the cytogenetic band 19q13.3, between the D19S412 and STD markers (Rosenberg et al., 1996; Smith et al., 2000) .
We previously described clonal chromosomal rearrangements in three glioblastoma cell lines (Magnani et al., 1999) that affected both homologs of chromosome 19. We have now analysed these rearrangements further using FISH mapping of the 19q breakpoints. Using three overlapping cosmids we have identified an amplified region in 19q13.2 that lies centromerically to the frequent LOH region in gliomas. The amplified region turned out to contain only MAP/microtubule affinity-regulating kinase 4 (MARK4) gene. This gene participates in the Wnt-signaling pathway and is considered a b-catenin/Tcf/LEF-regulated gene (Kato et al., 2001) . MARK4 is expressed in two alternatively spliced isoforms: MARK4S, exclusively expressed in the brain, and MARK4L, which results from alternative splicing that leads to exon 16 skipping (Kato et al., 2001) .
In the present work we show that MARK4L isoform, which is downregulated in normal brain, is upregulated in all gliomas and overexpressed by intrachromosomal duplication in three independent glioblastoma cell lines.
Results

FISH mapping of 19q breakpoints in the MI-4 glioblastoma cell line
Using conventional cytogenetic and FISH analysis we previously reported that the glioma cell line, MI-4, carries several complex chromosomal rearrangements affecting both homologs of chromosome 19 with breakpoints in the pericentromeric 19q region underlying the formation of three derivative chromosomes. One copy of chromosome 19 undergoes a split and translocation to chromosomes 1 and 9, while the other copy carries an interstitial deletion where part of the deleted region has become inserted into a derivative unidentified chromosome (Magnani et al., 1999) . To characterize the chromosome 19q breakpoints more accurately, we used YACs from the WC19 contig (generated by the Lawrence Livermore National Laboratory) in order to define clones that crossed the translocation breakpoints. YAC 784g9, which maps to 19q13.1 (Figure 1 ), demonstrated hybridization signal on both the der(19) and der(9), indicating that it spans the 19q breakpoint (Figure 2a) . YAC 877f9, which maps more centromerically, gave a fluorescent signal only on der(19), whereas a more telomeric YAC, 896g5, hybridized only to the der(9), indicating that they lie proximally and distally to the breakpoint, respectively (data not shown).
The breakpoints associated with the interstitial q13.2-13.31 deletion on the other copy of chromosome 19 were also analysed, as shown in red in the ideogram in Figure 2 . In this case, YAC 857c10 demonstrated a split signal between 19q and a chromosome defined as der(1) by using a whole chromosome paint (WCP) (data not shown), thus defining the centromeric breakpoint position on 19 (Figure 2b ). The position of the proximal breakpoint for this deletion was shown by FISH to lie within YAC 202h12. Indeed, this clone gave a split signal on der(1) and der(19(q13.1)) confirming the 
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A Beghini et al insertion of chromosome material from the homologous 19q13.2-13.31 region in der(19). The signal intensity on der(9), however, was much stronger than expected ( Figure 2c ). The position of the distal breakpoint of the interstitial q13.2-13.31 deletion remains to be identified. To define the region of 19q that is apparently amplified on the der(9) chromosome more accurately, we identified a series of overlapping BACs spanning the genomic interval defined by YAC 202h12. BAC 523h10 showed an identical hybridization pattern on der(1) and der(19) to YAC 202h12, where again a highly amplified signal was seen on der(9) as compared to that observed on normal metaphase chromosomes (Figure 2d ).
Defining the over-represented 19q13.2 interval in the MI-4 cell line FISH analysis of MI-4 chromosomes using BAC 179k24, which overlaps with BAC 523h10 at the centromeric side, demonstrated a signal of regular intensity on der (9) (data not shown), suggesting that the amplified region involves only the telomeric portion of BAC 523h10. Using BAC 315i20 (Figure 1 ), an amplified signal was also seen on the der(9) chromosome but no split signal was observed (data not shown). Finally, FISH analysis of BAC 433i18, which overlaps at the very proximal (telomeric) end of b315i20 ( Figure 1 ) showed only normal signal intensities demonstrating that it was not amplified (data not shown). To further refine the extent of the amplified region, cosmid R32611 was hybridized to MI-4 chromosomes and shown to cross the 19q13.2-13.31 breakpoint, although it did not give an enhanced signal (data not shown). Thus, the combined FISH results suggest that the amplified signal is located in a 150 kb region, covered by the contig of cosmids F18718, R31237, R33632 and F19186 (Figure 1 ). FISH analysis of the R13237 cosmid gave a signal on der(19(q13.1)) and a 2) shows a split on der(1) and der(19) that a further rearrangement affected the 19q13.2 region excised from chromosome 19q (light gray arrow). A much more intense signal than expected is visible on der(9). (d) Bac 523h10 spanning a telomeric portion of Yac 202h12 reproduces the same FISH pattern giving a split signal on der(1) and der(19) and a highly amplified signal on der (9) MARK4 is upregulated and amplified in gliomas A Beghini et al duplicated signal on der(9) in all of the metaphases analysed ( Figure 3a) . A quadruplet of close spots plus an additional spot could be seen on the nuclei as well (Figure 3b ), confirming that 19q13.2 amplification is homogeneously present in the MI-4 cell line.
Further refinement of the amplified region was obtained by using the F18718 and R33632 cosmids that overlap both ends of the amplified R31237 cosmid (Figure 1 ). Both of these clones gave a single signal on both der(19) and der(9) (data not shown). However, in a few metaphases, the signals on der(9) appeared duplicated but with low intensity, suggesting that only a small portion of these probes is included in the 19q13.2 amplicon (data not shown).
Duplication/amplification of 19q13.2. in the glioblastoma cell lines
Since chromosome 19 alterations occur frequently in gliomas, we extended our FISH analysis to other glioblastoma cell lines. Using a whole chromosome 19 paint we identified two other cell lines, MI-7 and GBM, which carried chromosomal rearrangements involving chromosome 19 that had previously escaped cytogenetic detection Perego et al., 1994) . The MI-7 cell line has a modal chromosome number of 59. Within the parental population there are two clones, one with two der(19) chromosomes and another with three or four copies of an apparently normal chromosome 19. The GBM cell line also displays a der(19) in some metaphases together with three or four copies of chromosome 19. Examples of these chromosome 19 abnormalities are shown in the insets of Figure 3c , d and f.
To investigate whether the genomic amplification that was seen in 19q13.2 in the MI-4 cell line was also present in these cell lines we applied the FISH analysis. Using the R31237 cosmid on MI-7 metaphases, a duplicated signal was seen on both the der(19) ( Figure 3c ) as well as on an iso19q-like chromosome ( Figure 3 ). This latter hybridization pattern was also observed in some metaphases from the GBM cell line (Figure 3e ). A subclone of this cell line showed a cluster of fluorescent spots on the derivative chromosome 19 in some metaphase spreads (inset of Figure 3e ).
We also hybridized the MARK4 cDNA probe to a Southern blot from MI-4 and GBM cell lines and confirmed the increased dosage of the gene as compared to normal control and the G32 glioblastoma cell line, which is devoid of 19q chromosomal rearrangements ( Figure 4c ).
Gene content of the contig cosmids R31237 and R33632, and cloning of the alternatively spliced isoforms of human MARK4
Computer-assisted analysis of the DNA sequence from cosmids R31237 and R33632, which centered on the amplified region in glioma cell lines, predicted several potential exons. BLAST analysis showed that these potential exons matched three independent cDNA clones; two partial coding sequences (CDS) isolated from anaplastic oligodendroglioma (AI869600, AI939391), and a complete CDS isolated from normal human brain (Nagase et al., 2001) . Comparison of the complete 3.6-kb cDNA with the genomic clone-derived sequence revealed the presence of a gene with 18 exons, containing a 688 amino-acid ORF (Figure 4a ). The independent cloning of the same gene has been recently described, which was identified as the MAP/microtubule affinity-regulating kinase 1 (MARK4) gene (Kato et al., 2001) . By using the cDNA isolated from the MI-4 glioblastoma cell line as a FISH probe to normal lymphocyte metaphases, we confirmed that the native location of the MARK4 gene is on chromosome 19q13.2 (data not shown).
A distinctive structural feature of human MARK4 is the alternative splicing-skipping of exon 16, which leads to a change in the reading frame and the generation of two different transcripts (Figure 4a ). One alternatively spliced isoform (MARK4L), which does not include exon 16, is predicted to encode for a 752 amino-acid peptide containing an ELKL-box/KA1 kinase-associated domain in the C-terminal region (Figure 4b ). The other isoform, named MARK4S, includes exon 16.
Upregulation and overexpression of MARK4L isoform in glioma
Using RT-PCR we investigated the expression profile of the MARK4 gene on tumor samples from eight glioma patients, including two OA (Figure 4d , lanes 1 and 2), three AA (Figure 4d , lanes 3, 4 and 8) and three GBM (Figure 4d , lanes 5-7), as compared to whole normal brain (WNB). The MARK4S isoform is prevalent in WNB, as previously described (Kato et al., 2001) , where the MARK4L isoform, lacking exon 16, can be only detected at low levels. Conversely, all tumors expressed the MARK4L isoform; detection of MARK4S isoform in four cases may be imputed to the admixture of other cell types, which is common in fresh tumors (Figure 4d ). Semiquantitative RT-PCR analysis was then performed on 26 glioma cell lines. Reaction conditions and the number of cycles were adjusted so that the reaction fell within the linear range of product amplification. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a gene with constitutive expression, served as an internal control (Fan et al., 1998) . Results confirmed the exclusive expression of the transcript lacking exon 16 (MARK4L) in all cases with variable transcript levels. Pooled RT-PCR data from the above glioma cell lines, subdivided into WHO grade I and II (n ¼ 10), grade III (n ¼ 11) and grade IV (n ¼ 5), showed expression levels of MARK4L isoform increasing with malignancy ( Figure 4e ).
We next investigated whether the intrachromosomal amplification of the MARK4 gene, observed in three human glioblastoma cell lines, might be associated with gene overexpression. MARK4 expression was evaluated in seven primary glioma cell lines, including five glioblastoma (WHO grade IV), one anaplastic oligoastrocytoma (WHO grade III), and one pilocytic Figure 5a) were measured by densitometric analysis and four of them showed increased expression compared to dHNPCs (Figure 5b ). The highest levels of MARK4 expression were detected in glioblastoma cell lines MI-7, GBM, and MI-4 and G32, including all cell lines carrying 19q amplification. Nevertheless, all the remaining cell lines showed definitely increased expression levels as compared to the proliferating control (Figure 5a and b) .
Expression of MARK4 mRNA isoforms during glial differentiation from neural progenitor cells
In order to check whether the MARK4L isoform upregulated in glioma tumors is normally expressed in undifferentiated or proliferative cells, we established a neural progenitor cell culture.
Normal human neural progenitor cells (HNPCs) were cultured as free floating spheroids (neurospheres) for 40 days (Svendsen et al., 1998) (Figure 6a) . RT-PCR analysis of HNPC cells showed high expression of the MARK4-L isoform only (Figure 6e ). To determine whether MARK4 expression is subject to regulation during glial differentiation, and whether the L isoform is downregulated during terminal differentiation, we plated HNPCs under culture conditions that induce glial differentiation. Neurospheres exposed to medium supplemented with fetal calf serum (FCS) rapidly attached to the plate, where cells with a glial morphology could be observed (Figure 6b) . Immunohistochemical analysis of glial acidic fibrillary protein (GFAP; an astrocyte marker; Marsden et al., 1983) 2 weeks after addition of FCS showed that these cells were weakly positive (Figure 6c) . The same cells were strongly positive for vimentin ( Figure 6d ) and nestin (data not shown), a pattern restricted to the precursor that generates only astrocytes . At 4 weeks after addition of FCS, the partially differentiated HNPCs (dHNPCs) proliferated to a limited degree and showed barely detectable levels of the MARK4L isoform (Figure 6e and f) . Thus, the MARK4L transcript was detected at high levels in HNPCs and its expression significantly downregulated upon their differentiation into glia.
Perturbation of MARK4 expression alters the proliferation of glioblastoma cells
To establish whether MARK4 regulates the proliferation capacity of glioblastoma cells, we perturbed its expression in the GBM and MI-7 cell lines, which overexpress it, using antisense oligonucleotides. Following transfection of phosphorothioate sense and antisense oligodeoxynucleotides (ODNs) into the GBM and MI-7 cell lines, only those cells treated with the antisense ODN suppressed MARK4 expression in both cell lines, as determined by RT-PCR analysis (Figure 7a ). To assess the effects of inhibition of MARK4 expression on tumor cell growth in both cell lines, we analysed 3 H-thymidine incorporation rate using a semiautomated cell harvesting system which was used to lyse the cells and precipitate the labeled DNA 1, 2 and 3 days after transfection. The radioactivity was then counted in a b-counter. Both cell lines treated with antisense ODN showed a significant reduction in 3 H-thymidine incorporation into cellular DNA, which indicates a reduction in cell proliferation (Figure 7b and c) .
Discussion
Structural alterations of chromosome 19q are frequently observed in human gliomas Magnani et al., 1999; Smith et al., 2000; Hartmann et al., 2002) and may represent an early oncogenic event MARK4 is upregulated and amplified in gliomas A Beghini et al in oligodendrogliomas (Bello et al., 1995) . We have previously identified a recurrent 19q11-12 breakpoint in glioblastoma cell lines that displayed several abnormalities involving chromosome 19q. In particular, the MI-4 glioblastoma cell line contained 19q rearrangements involving both homologs which resulted in the formation of three derivative chromosomes (Magnani et al., 1999) . In the present study, we mapped by FISH analysis the breakpoints underlying the complex 19q rearrangements in the MI-4 cell line and identified the 19q13.2 band as target of amplification, a feature significantly shared by the MI-7 and GBM glioblastoma cell lines.
Attempts at defining the amplified chromosomal domain led to identify the R31237 cosmid as responsible for the multiple FISH signals. This result shown in all cell lines by a variety of typical chromosomal figures indicates the presence of DNA amplification in forms other than DMs and HSRs that represent the early evidence of gene amplification in gliomas (Bigner et al., 1988) .
Interestingly the R31237 cosmid turned out to contain only one gene, MARK4, which was recently cloned and has been shown to be downregulated in response to decreased Tcf/LEF1 activity. This feature suggests that it may play a role as a messenger in the Wnt-signaling pathway (Kato et al., 2001 ). This pathway is involved in various developmental and oncogenic processes, including the positive regulation of cell cycle progression and the negative regulation of cell cycle exit by the b-catenin/ TCF pathway in neural precursors (Roth et al., 2000; Satoh and Kuroda, 2000; Megason and McMahon, 2002) . To further characterize the expression profile of MARK4 in both committed neural progenitors as well as postmitotic differentiated cells, we exposed cultured neurospheres to differentiation conditions. A correlation between MARK4 expression and the rates of proliferation/differentiation was also found in these cells, since constitutive expression in HNPCs was downregulated as a result of differentiation into glial cells. These expression data, together with the suggested role of MARK4 in Wnt signaling, imply that MARK4 expression might be associated with G1 to S cell cycle progression of HNPCs. Conversely, loss of expression might correspond to G1 to G0 cell cycle exit of differentiated glial cells. These suggestive findings are supported by two recent lines of evidence showing that: (i) activation of Wnt signaling primarily regulates cell Expression results that we obtained on glioma cell lines and primary gliomas showed as a common trend the upregulation of MARK4 mitogenic-associated isoform, usually switched off in nonproliferating glial cells. The re-expression of MARK4L in tumor cells, normally restricted to undifferentiated or proliferative cells, may imply that MARK4L is necessary to allow glial proliferation.
MARK4 was also found to be target of intrachromosomal amplification leading to MARK4L overexpression in at least three glioblastoma cell lines. To evaluate the growth-promoting activity of MARK4, we have perturbed its expression by transfecting antisense ODNs into the glioblastoma cell lines showing MARK4 amplification and monitored the acquired loss in the proliferation capacity. Given the MARK4 is a proliferation-associated gene, its overexpression might be linked to selective advantage and clonal expansion. Other mechanisms such as aberrant Wnt pathway activation may also be involved in MARK4L overexpression as suggested by the observation of a fourth overexpressing glioblastoma cell line (G32) not displaying cytogenetic amplification (Zurawel et al., 1998; Koch et al., 2001) . Although overexpression of the MARK4 gene represents an entirely new pathogenetic mechanism in gliomagenesis, the fact that this is achieved mainly by intrachromosomal amplification, closely resembles for the situation of genes such as MET in human gastric carcinoma and more generally of genes residing within fragile sites in a variety of human and experimental systems (Coquelle et al., 1997; Hellman et al., 2002) .
Allelic loss at 19q13.3, a well-documented finding in gliomas (Hartmann et al., 2002) , may be accounted for by mitotic recombination that may be enhanced in this highly unstable region (Vrieling, 2001 ). We propose a role for the 19q13 fragile site (Sutherland and Richards, 1995) in driving recurrent breaks responsible to induce MARK4 amplification accompanied by LOH at loci proximal to the amplification site (Reifenberger et al., 1995) .
Materials and methods
Cell cultures
The following cell lines: MI-4, MI-7, GBM, G32, T60, MI-20, G91 as well as all the others glioma cell lines used for expression analysis were obtained from biopsy specimens as described elsewhere Perego et al., 1994) . Subsequently, all cell lines were maintained by serial passages in RPMI 1640 medium containing 5% FCS at 371C in a 5% CO 2 atmosphere. The MI-4 and GBM cell lines were used at 30th passage and all other cell lines within the first 20 passages. Cytogenetic analysis was performed on both fresh tumors and cell lines as described previously. Tumor tissues were mechanically ground, resuspended in complete medium and plated onto coverslips. Chromosomes spreads were set up from cultures harvested before they become confluent Perego et al., 1994) .
Cell lines MI-4 and GBM presented the same stemline karyotype primarily described and MI-7 only presented a sideline of 59 chromosomes when examined by FISH.
HNPCs (Clonetics) were grown in the form of spheroids for 40 days in serum-free neural progenitor cell maintenance medium, BulletKit (Clonetics). Every 14 days the spheres were mechanically dissociated using a Pasteur pipette with a flamereduced bore size, split 1 : 2 and reseeded into fresh medium. After 40 days, cells were processed for expression analysis of MARK4 gene. Moreover, a T75 flask and few chamber-slides were set up with a suspension of spheres and maintained in NPBMtm medium supplemented with 5% FCS to allow in vitro attachment. On day 14, HNPCs were processed for analysis of expression levels of the MARK4L isoform and chamber-slides were used for immunocytochemistry analysis.
Fluorescent in situ hybridization
CEPH YAC clones and CITB human BAC clones were obtained from Research Genetics. Chromosome 19 cosmids, LLNL-R32611, LLNL-F18718, LLNL-R31237, LLNL-R33632, LLNL-F19186, LLNL-F15123, LLNL-F10080, LLNL-F13544, LLNL-F20720 and LLNL-R32889 were obtained from the Lawrence Livermore National Laboratory. A WCP1 probe, to identify chromosome der(1), was purchased from Cambio (Cambridge, GB). A MARK4 cDNA probe lacking exon 16 was isolated from HNPCs to establish its endogenous location on normal lymphocyte metaphase chromosomes. YAC, BAC and cosmid extractions were carried out according to standard alkaline lysis procedures . Total DNA from the yeast host cell containing the YAC of interest was used as a template to synthesize a humanspecific probe from the YAC DNA by using inter-ALU polymerase chain reaction (PCR) as described previously . Standard techniques were used to prepare metaphase chromosome spreads from glioma cell lines and lymphocyte cultures. All probes, except wcp1, were labeled with digoxigenin-11-dUTP by using the Dig-Nick translation Mix (Roche). From the labeled probes 200 ng of YAC or BAC DNA, or 350 ng of cosmid DNA were mixed with 25-fold excess of human Cot-1 DNA in a final volume of 15 ml of hybridization solution. For in situ experiments with the cDNA probe, we omitted the Cot-1 DNA in the hybridization mix. The FISH procedure, as well as the detection of digoxigenin-labeled probes, has been described elsewhere . Chromosome spreads were viewed using a CCD camera (Photometrics) and Smartcapture software (Vysis). The images were edited using HighFISH software (Casti Imaging).
Southern blot hybridization
We used Southern blotting to investigate the status of amplification of MARK4 gene. For Southern blot, 15 mg of genomic DNA from each cell line or from normal lymphocytes were digested with EcoRI and EcoRV and separated on 0.8% agarose, then transferred onto a nylon membrane (Amersham) with SSC20X o/n. The DNA was crosslinked to the membrane in an oven at 801C for 8 h. The a 32 P-labeled probe (including exons 1-12) used for hybridization was prepared by random priming using the Random Primed DNA Labelling Kit (Roche) and then purified on a Nick Column containing Sephadex G-50 (Pharmacia Biotech). Hybridization was performed at 681C for 2 h with Express Hyb hybridization solution (Clontech). The blot was then washed twice 20 min in a solution of 2 Â SSC/0.05% SDS at room temperature (RT) and twice 20 min in a solution of 0.1 Â SSC/0.1% SDS at RT, before exposure to film for 72 h at À801C.
Semiquantitative RT-PCR analysis
Total RNA was extracted from all glioma cell lines using RNAqueoust-4 PCR (Ambion) according to the manufacturer's instructions. The extracted RNA was treated with DNase (Ambion) to exclude false results by DNA contamination. Aliquots of RNA (0.8 mg) were then reverse transcribed using ThermoScriptt reverse transcriptase (Invitrogen). Aliquots of cDNA corresponding to 20 ng of original RNA were used for PCR amplification of MARK4 and GAPDH. GAPDH was amplified as a control, resulting in a 312 bp product with fluorescent-labeled forward (5 0 -Hex-ACAA-CAGCCTCAAGATCATCAG-3 0 ) and reverse (5 0 -GGTCCACCACTGACACGTTG-3 0 ) primers with the following PCR conditions: 24 cycles at, 941C, 30 min; 571C, 30 min; 721C, 30 min. MARK4 PCR, detecting both the MARK4S (363 bp) and MARK4L (263 bp) isoforms, was performed using fluorescent-labeled forward (5 0 -Fam-CTGACCTCCAAACTGACCCG) and reverse (5 0 -CGAAGTGGGACAGGGGCTC-3 0 ) primers, flanking the alternative exon 16, with the following conditions: 27 cycles at 941C, 35 min; 611C, 25 min; 721C, 15 min. Preliminary RT-PCR experiments were conducted using various cycle numbers and then one of these was chosen. Various amounts of the RT reaction were used to determine the amount of cDNA for analysis of PCR within the linear range. Fluorescent PCR products were analysed, after electrophoresis through 1.8% agarose gels, using Typhoon 9200 fluorescent densitometry (Amersham Pharmacia) and quantitated by Image Quant Software (Molecular dynamics, Amersham Pharmacia).
Immunocytochemistry
We performed an immunocytochemical study for GFAP and vimentin to determine the presence of glial differentiation. Monolayer cells cultured on coverslips were rinsed in Tris buffer and fixed in Carnoy for 10 min, then rehydrated, immersed for 10 min in 0.05% Triton solution, rinsed in distilled water, incubated for 10 min in 3% hydrogen peroxide and washed in Tris buffer three times for 5 min. The slides were covered with 5% normal goat serum in Tris buffer for 20 min, then incubated for 2 h at 371C with a 1 : 100 dilution of primary anti-GFAP monoclonal antibody (DAKO) or a 1 : 20 dilution of primary antivimentin monoclonal antibody (DAKO). After three washes in Tris buffer, the slides were incubated 1 h in EnVision + , Peroxidase, Mouse secondary (DAKO). Finally, the slides were washed and reacted with diaminobenzidine in 0.1 m Tris buffer with 0.03% hydrogen peroxide, rinsed in distilled water, counterstained and mounted. The cells weakly expressed GFAP, and showed marked immunostaining for vimentin, displaying a primitive glial differentiation.
ODNs transfection and proliferation assay
Glioblastoma cell lines MI-7 and GBM were cultured with Opti-MEM medium (Invitrogen) for 24 h during which the cells reached 80-90% confluence. Cells were transfected with synthetic phosphorothioate ODNs (0.1-0.2 mm final concentration) in LipofectAMINEt2000 (Invitrogen) containing Opti-MEM in accordance with the manufacturer's instructions and incubated for 6 h. For RT-PCR analysis, incubation was continued for 12 h before total RNA extraction.
After transfection 2 Â 10 3 cells were plated in microtiter plates in four replicates. H-thymidine (1 mCi/ml) was added 24 h before harvesting the cells. A semiautomated cell harvesting apparatus was used to lyse the cells with water and precipitate the labeled DNA on glass fiber filters. The filter pads were dried and counted in a b-counter after addition of the scintillation fluid.
